{
    "ticker": "LQDA",
    "name": "Liquidia Technologies, Inc.",
    "description": "Liquidia Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products for patients with serious diseases. Founded in 2004, Liquidia utilizes its proprietary PRINT technology, which enables the precise fabrication of nanoparticles, to create formulations that enhance the delivery and efficacy of drugs. The company is primarily engaged in developing treatments for pulmonary diseases, particularly pulmonary arterial hypertension (PAH). Liquidia's lead product candidate, LIQ865, is specifically designed to offer a new treatment option for patients suffering from PAH, aiming to improve patient outcomes through its innovative delivery mechanism. The company is committed to advancing its pipeline and aims to address unmet medical needs through its research and development efforts. With a strong focus on innovation and patient-centric solutions, Liquidia is poised to make significant contributions to the biopharmaceutical landscape, leveraging its proprietary technology to create next-generation therapies that enhance the quality of life for patients.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2004",
    "website": "https://www.liquidia.com",
    "ceo": "Roger Jeffs",
    "social_media": {
        "twitter": "https://twitter.com/LiquidiaTech",
        "linkedin": "https://www.linkedin.com/company/liquidia-technologies/"
    },
    "investor_relations": "https://investors.liquidia.com",
    "key_executives": [
        {
            "name": "Roger Jeffs",
            "position": "CEO"
        },
        {
            "name": "Richard D. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Products",
            "products": [
                "LIQ865"
            ]
        }
    ],
    "seo": {
        "meta_title": "Liquidia Technologies, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Liquidia Technologies, Inc., a biopharmaceutical company focused on developing innovative therapeutic products for serious diseases. Learn about their unique PRINT technology and product pipeline.",
        "keywords": [
            "Liquidia",
            "Biopharmaceuticals",
            "Pulmonary Arterial Hypertension",
            "PRINT Technology",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Liquidia Technologies specialize in?",
            "answer": "Liquidia Technologies specializes in developing innovative therapeutic products for serious diseases, particularly in pulmonary medicine."
        },
        {
            "question": "Who is the CEO of Liquidia Technologies?",
            "answer": "Roger Jeffs is the CEO of Liquidia Technologies, Inc."
        },
        {
            "question": "Where is Liquidia headquartered?",
            "answer": "Liquidia is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What is Liquidia's lead product candidate?",
            "answer": "Liquidia's lead product candidate is LIQ865, aimed at treating pulmonary arterial hypertension."
        },
        {
            "question": "When was Liquidia founded?",
            "answer": "Liquidia was founded in 2004."
        }
    ],
    "competitors": [
        "VRTX",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "ABBV",
        "MRK"
    ]
}